Table of Contents
PISCATAWAY, N.J. –Camber Pharmaceuticals is excited to announce the addition of nimodipine oral solution.
Nimodipine oral solution is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition.
Nimodipine oral solution 60 mg/20 mL (3 mg/mL) is available and packaged in a 16-ounce bottle.
To find out more information on nimodipine oral solution, visit: www.camberpharma.com/nimodipine
